Actively Recruiting
A Multi-Center Natural History Study of Urothelial and Rare Genitourinary Tract Cancers
Led by National Cancer Institute (NCI) · Updated on 2026-06-05
1100
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying tumors in the genitourinary (GU) tract, which includes cancers of the kidney, bladder, prostate, testicles, penis, and neuroendocrine cancers. Some of these tumors are rare and not well represented in treatment studies or tissue banks, making it difficult to establish standard care. This research aims to better understand both common and rare GU tumors by collecting detailed patient information over time. Participants in this long-term, multi-center observational study will provide medical history and may undergo physical exams, blood and urine sample collection, and surveys about family cancer history. Imaging scans of the chest, abdomen, and pelvis may be performed, sometimes with contrast injections. Patients may also provide existing tumor samples or optional biopsies. Samples may be used for genetic testing, and various scientific analyses including genomics and immune monitoring will be conducted. Throughout the study, participants will have regular follow-up visits and ongoing monitoring of their health, either at the research site or through coordination with their home doctors. Researchers will track disease patterns, treatment responses, and disease progression to characterize the natural history of GU cancers. This study will continue to follow patients over their lifetime to gather comprehensive data and improve future diagnosis and treatment strategies.
CONDITIONS
Brief Title
A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must have confirmed urothelial or rare genitourinary cancer, including but not limited to small cell carcinoma of the bladder, adenocarcinoma of the bladder, squamous cell carcinoma of the bladder, plasmacytoid urothelial carcinoma, penile cancer, testicular cancer, sarcomatoid renal cell carcinoma, renal medullary carcinoma, and other rare variants.
- Participants must be 18 years of age or older.
- Participants must be able to understand and willing to sign a written informed consent document.
You will not qualify if you...
- None
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 20 years
Participants are followed throughout the course of their illnesses with collection of medical history, tissue samples, blood, and clinical information to study disease patterns, progression, and response to therapies.
Visits occur periodically throughout the study duration
Trial Site Locations
Total: 1 location
1
National Institutes of Health Clinical Center
Bethesda, Maryland, United States, 20892
Actively Recruiting
Research Team
T
Tzu-Fang Wang, R.N.
A
Andrea B Apolo, M.D.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here